Vida Ventures — Full Portfolio

Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.

BiotechCambridge, US

Kiran Reddy(Executive Officer, Director)

BoardNicholas G. Galakatos(Director)

Board seatStefan Vitorovic· per SEC Form D · $10M raise · filed Jun 2019

Co-investorsOCV PartnersClarus

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)

BoardOWEN WITTE(Director)

Co-investorsAvoro Capital AdvisorsForesite CapitalTPG

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)Oxana Beskrovnaya, Ph.D.(Executive Officer)

BoardLawrence Klein, Ph.D.(Director)

Co-investorsAtlas VentureMPM BioImpactForbionHercules Capital, Inc.

A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.

BiotechHealthtechNew York, US

Zachary Prensky(Executive Officer, Director)Lauren Stipp(Executive Officer)Mark Panoff(Executive Officer)

BoardEdmund Sullivan(Director)Vincent Grattan(Director)

Co-investorsPontifax Venture CapitalTarnagulla VenturesTCG Crossover

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.

BiotechDigital HealthMedical Devices

Co-investorsYsios CapitalJeito Capital

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsHealthCapJeito CapitalNovo HoldingsOrbiMedPontifax Venture CapitalRA Capital+2 more

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)

Co-investorsAtlas VentureLightspeed Venture PartnersOmega FundsTenmileAbingworthBiotechnology Value Fund

InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.

BiotechDeep TechMedical DevicesSeattle, US

K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)Amanda J. Redig(Chief Medical Officer)Scott Lesley(President & CSO)Pamela Holland(SVP of Biology)Sally Johnson(Chief People Officer)

Co-investorsMRL Ventures FundThe Column Group

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechHealthtechSouth San Francisco, US

Kenneth Greenberg(Co-Founder, President & CEO)in

Co-investorsLeaps by BayerFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo CapitalARCH Venture Partners+1 more

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.

BiotechHealthtechAgoura Hills, US

C. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)

BoardSrini Akkaraju(Director)inDavid Goeddel(Director)

Board seatHelen S. Kim· per SEC Form D

Co-investorsNextech InvestSamsara BioCapitalThe Column Group

New York, US

Jesse Horwitz(Executive Officer, Director)Benjamin Cogan(Executive Officer, Director)Eric Osman(Executive Officer, Director)

Board seatJoshua Kazam· per SEC Form D · $500K raise · filed Jan 2018

ByHeart is an infant formula company navigating an FDA return-to-market process following a product outbreak investigation.

ConsumerDirect to ConsumerFoodTechHealthtechNew York, US

Mia B. Funt(Executive Officer, Director)inRon Belldegrun(Executive Officer, Director, Promoter)inMia Funt(Founder)inGeorg Krause-Vilmar(Executive Officer)Niall Mullane(Executive Officer)

BoardAmy Schulman(Director)in

Board seatArie BelldegrunJoshua Kazam· per SEC Form D · $95.5M raise · filed May 2026

Co-investorsEvolution VC PartnersOCV PartnersPolaris PartnersRed Sea Ventures

Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.

BiotechHealthtechNew York, US

Sean Algeo(Executive Officer, Promoter)Mark A. McCamish(Executive Officer, Director)David M. Tanen(Executive Officer, Promoter)

BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in

Board seatHelen S. KimJoshua KazamArie Belldegrun· per SEC Form D

Co-investorsGV (Google Ventures)Nextech InvestWellington Management

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Board seatJoshua Kazam· per SEC Form D

Co-investorsEcoR1 CapitalGV (Google Ventures)Nextech Invest

HealthtechNew York, US

Ron Belldegrun(Executive Officer, Director)Georg Krause-Vilmar(Executive Officer)Mia B. Funt(Executive Officer, Director)Devon Kuehn(Executive Officer)Niall Mullane(Executive Officer)Neil Betteridge(Executive Officer)

Board seatArie BelldegrunJoshua Kazam· per SEC Form D · $20.3M raise · filed Jul 2026

Co-investorsOCV Partners

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)

Board seatRajul Jain· per SEC Form D

Co-investorsEcoR1 CapitalJeito CapitalTPG

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Board seatHelen S. Kim· per SEC Form D

Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more

New York, US

William Herlands(Executive Officer, Director)Jesse Horwitz(Executive Officer, Director)Drew Tarlow(Director)Benjamin Cogan(Executive Officer, Director)

BoardRick Heitzmann(Director)

Board seatJoshua Kazam· per SEC Form D · $500K raise · filed Jan 2018

Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.

AI & Machine LearningBiotechMedical DevicesWatertown, US

Timothy A. Springer(Co-Founder)Andrew C. KruseTimothy Springer(Director)Andrew Kruse(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)

Board seatStefan Vitorovic· per SEC Form D

Co-investorsEcoR1 CapitalAlly Bridge GroupClarusPolaris PartnersSoleus Capital

New York, US

Christopher Wilfong(Executive Officer)Alex Kaufman(Executive Officer, Director)

BoardRon Belldegrun(Director)Joshua A. Kazam(Director, Promoter)David M. Tanen(Director, Promoter)Gregory F. Kiernan(Director, Promoter)

Board seatJoshua Kazam· per SEC Form D · $6.6M raise · filed Feb 2017

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)

Board seatStefan Vitorovic· per SEC Form D

Co-investorsAtlas VentureLightstone VenturesHatteras Venture PartnersLongwood Fund

New York, US

Jesse Horwitz(Executive Officer, Director)Benjamin Cogan(Executive Officer, Director)

BoardLeonard Potter(Director)Rick Heitzmann(Director)Kejia Sun(Director)

Board seatJoshua Kazam· per SEC Form D · $16.5M raise · filed Mar 2017

Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.

BiotechHealthtechNew York, US

Samuel Bakhoum(Co-Founder & Chief Scientific Officer)Lewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)David Southwell(Executive Officer, Director)

BoardRobert Mittendorff(Director)

Board seatStefan Vitorovic· per SEC Form D

Co-investorsDroia VenturesARCH Venture PartnersB Capital GroupB4 Capital

BiotechWatertown, US

Kathy Bergsteinsson(Executive Officer)Kathy Yi(Executive Officer)Joseph Knowles(Executive Officer, Director)

BoardLucio Iannone(Director)Arjun Goyal(Director)Jill DeSimone(Director)

Co-investorsLeaps by Bayer

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.

AI & Machine LearningBiotechDeep TechSan Diego, US

Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)

BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in

Co-investorsCanaan PartnersNextech InvestOrbiMedDigitalis VenturesNVIDIA

AskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease.

BiotechDeep TechHealthtechDurham, US

Co-investorsTPGColumbus Venture Partners

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

Zaneta Odrowaz(Founder)in

Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesGoldman Sachs

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio Partners

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)Ramin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsPfizer Venture InvestmentsRA CapitalSofinnova Ventures

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsAdvent Life SciencesEcoR1 CapitalForesite CapitalMedicxiOberland CapitalScion Life Sciences+1 more

BiotechMedical DevicesNew Haven, US

Scott Phillips(Executive Officer)

BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in

Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsFrazier Life SciencesRA CapitalTaiho Ventures, LLC

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyHBM Healthcare Investments+4 more

Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.

Biotech

Co-investorsWestlake Village BioPartners

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsNextech InvestThe Column Group

Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.

Biotech

Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.

BiotechHealthtechMedical Devices

Co-investorsOak HC/FTOak Investment Partners

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US

Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpact+1 more

Co-investorsMPM BioImpact

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)

BoardMaha Katabi(Director)Perry Nisen(Executive Officer, Director)Maria Fardis(Director)

Co-investorsLongitude CapitalSofinnova VenturesBiotechnology Value FundFrazier Life Sciences

BiotechBoston, US

Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)

Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestLightspeed Venture Partners+2 more

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound enhancing agents) to deliver genetic payloads to targeted sites in a redosable manner.

BiotechDeep TechDigital Health

Kenneth Greenberg(Founder)in

Co-investorsARCH Venture PartnersLeaps by BayerSymBiosisUCB VenturesVivo Capital

Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease.

AI & Machine LearningBiotechDeep Tech

Victor Kotelianski(Founder)Daniel Anderson(Founder)Robert Langer(Founder)Marino Zerial(Founder)Brad Pentelute(Founder)Amir Nashat(Chief Executive Officer)

Co-investorsLeaps by BayerBessemer Venture PartnersSafar Partners

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)

BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in

Co-investorsAndreessen Horowitzabrdn plcBiotechnology Value FundForesite CapitalHillhouse InvestmentOmega Funds+1 more